Literature DB >> 20662075

Interphase fluorescence in situ hybridization on selected plasma cells is superior in the detection of cytogenetic aberrations in plasma cell dyscrasia.

Natalie Put1, Heidi Lemmens, Iwona Wlodarska, Peter Konings, Yves Moreau, Anne Hagemeijer, Peter Vandenberghe, Lucienne Michaux.   

Abstract

Interphase fluorescence in situ hybridization (FISH) detects nonrandom cytogenetic abnormalities in plasma cell (PC) dyscrasia according to PC burden. However, when performed on cultured whole bone marrow (BM), it often fails to detect these aberrations. We have compared this interphase FISH technique with FISH after PC purification or identification to detect recurrent aberrations. In this study, 235 BM samples were collected from patients with multiple myeloma (MM) or related PC disorders regardless of disease status. All samples were analyzed in parallel. Clonal abnormalities were detected in 34.9% of cultured samples compared with 71.0% PC selected samples (P < 0.001). Moreover, FISH on PCs allowed to detect more abnormalities per case (P < 0.001) and identified higher percentages of abnormal nuclei (P < 0.001). This study indicates that FISH on PCs is the preferred technique for routine cytogenetic investigation of MM.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20662075     DOI: 10.1002/gcc.20809

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  3 in total

1.  Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells.

Authors:  Martin Schmidt-Hieber; María Laura Gutiérrez; Martin Pérez-Andrés; Bruno Paiva; Ana Rasillo; Maria Dolores Tabernero; José Maria Sayagués; Antonio Lopez; Paloma Bárcena; María Luz Sanchez; Norma C Gutiérrez; Jesus F San Miguel; Alberto Orfao
Journal:  Haematologica       Date:  2012-08-28       Impact factor: 9.941

2.  RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response.

Authors:  I J F Hofman; M van Duin; E De Bruyne; L Fancello; G Mulligan; E Geerdens; E Garelli; C Mancini; H Lemmens; M Delforge; P Vandenberghe; I Wlodarska; A Aspesi; L Michaux; K Vanderkerken; P Sonneveld; K De Keersmaecker
Journal:  Leukemia       Date:  2016-12-02       Impact factor: 11.528

3.  Validation of interphase fluorescence in situ hybridization (iFISH) for multiple myeloma using CD138 positive cells.

Authors:  Renata Kiyomi Kishimoto; Sarah Lee Vaughan Vulcani de Freitas; Cristina Alonso Ratis; Daniela Borri; Roberta Sitnik; Elvira Deolinda Rodrigues Pereira Velloso
Journal:  Rev Bras Hematol Hemoter       Date:  2016-02-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.